# Gabriel N. Hortobagyi

Source: https://onco.cc/people/gabriel-hortobagyi/  
OnCo record `gabriel-hortobagyi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease.

## Summary

Gabriel Hortobagyi has run breast cancer trials at MD Anderson for four decades and was principal investigator of MONALEESA-2, which showed ribociclib plus letrozole improves progression-free and then overall survival in postmenopausal HR-positive advanced breast cancer. He has chaired ASCO and helped write the AJCC staging system for breast cancer. His work continues on endocrine resistance and adjuvant CDK4/6 inhibition.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; trialist
- Role: Professor of Breast Medical Oncology, MD Anderson Cancer Center
- Specialisms: Breast cancer; CDK4/6 inhibitors; Endocrine therapy; Neoadjuvant therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Inflammatory breast cancer](https://onco.cc/cancers/inflammatory-breast-cancer/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/)
- drugs: [Ribociclib](https://onco.cc/drugs/ribociclib/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [MONALEESA-2](https://onco.cc/trials/monaleesa-2/), [NATALEE](https://onco.cc/trials/natalee/)
- key papers: [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/gabriel-hortobagyi.json